Ensaculin

Ensaculin
Clinical data
ATC code	none;
Pharmacokinetic data
Elimination half-life	13.7 hours
Identifiers
	IUPAC name 7-methoxy-6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy]-3,4-dimethylchromen-2-one;
CAS Number	155773-59-4 ;
PubChem CID	208923;
ChemSpider	181019 ;
UNII	869PGR00AT;
ChEMBL	ChEMBL1963107 ;
CompTox Dashboard (EPA)	DTXSID10870034 ;
Chemical and physical data
Formula	C26H32N2O5
Molar mass	452.551 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C/4Oc3cc(OC)c(OCCCN2CCN(c1ccccc1OC)CC2)cc3\C(=C\4C)C;
	InChI InChI=1S/C26H32N2O5/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3/h5-6,8-9,16-17H,7,10-15H2,1-4H3 ; Key:FQELZLMTAPJJOL-UHFFFAOYSA-N ;
	(what is this?) (verify)

Ensaculin (KA-672) is a drug from the coumarin family, which has been researched as a potential treatment for dementia. It acts on a number of receptor systems, being both a weak NMDA antagonist and a 5HT_1A agonist.^[1]^[2] Animal studies have shown promising nootropic effects,^[3]^[4] although efficacy in humans has yet to be proven. It was well tolerated in human trials, with the main side effect being orthostatic hypotension (low blood pressure upon standing).^[5]